Monday, June 5, 2023
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Cancer

New radionuclide therapy identified for HER2-positive breast cancer patients

September 29, 2021
in Cancer
0
Share on FacebookShare on Twitter

Reston, VA (September 28, 2021)—A promising radionuclide treatment may offer new therapeutic options for breast cancer patients, according to research published in The Journal of Nuclear Medicine. The treatment combines radioactive iodine therapy with single-domain antibodies that target the human epidermal growth factor receptor type 2 (HER2) antigen to destroy cancer cells. This first-in-human study demonstrates the safety and efficacy of the radionuclide in patients with HER2-positive breast cancer.

Uptake in bone metastasis.

Credit: Image created by M. Keyaerts, University Hospital of Brussels (UZ Brussel), Belgium.

Reston, VA (September 28, 2021)—A promising radionuclide treatment may offer new therapeutic options for breast cancer patients, according to research published in The Journal of Nuclear Medicine. The treatment combines radioactive iodine therapy with single-domain antibodies that target the human epidermal growth factor receptor type 2 (HER2) antigen to destroy cancer cells. This first-in-human study demonstrates the safety and efficacy of the radionuclide in patients with HER2-positive breast cancer.

Treatment of metastatic HER2-positive breast cancer has made great progress in recent years; nevertheless, the disease remains incurable. Today, no HER2-targeting radiopharmaceuticals are available to patients. With the development of the new targeted radionuclide theranostic agent, 131I-GMIB-Anti-HER2-VHH1, researchers sought to evaluate its safety, biodistribution, radiation dosimetry and tumor-imaging potential with the goal to introduce a new mechanism of action in the treatment of HER2-positive breast cancer.

In the study, six healthy volunteers and three HER2-positive breast cancer patients received injections of 131I-GMIB-Anti-HER2-VHH1. Vital signs and bloodwork, as well as open-ended questions, were used to assess the safety of the radionuclide. Whole-body imaging was conducted to ascertain biodistribution information and the resulting image data determined the dosimetry. In the three subjects with breast cancer, imaging was also used to measure tumor uptake.

131I-GMIB-anti-HER2-VHH1 was found to be safe and stable after administration and to clear rapidly from the blood in healthy volunteers. The tracer accumulated in metastatic sites of patients with HER2-positive breast cancer.

“This research is the first step in the clinical development of 131I-GMIB-Anti-HER2-VHH1 for the treatment of this devastating cancer indication, said Marleen Keyaerts, MD, PhD, nuclear medicine physician at the University Hospital of Brussels in Jette, Belgium, and principal investigator of the phase I study. “As a result of this study, multicenter dose escalation and therapeutic clinical investigation of 131I-GMIB-anti-HER2-VHH1 in patients with HER2-positive breast and gastric cancer is underway.”

According to study sponsor Tony Lahoutte, MD, PhD, chief scientific officer of Precirix, single-domain antibodies, such as 131I-GMIB-Anti-HER2-VHH1, could prove to be very beneficial in the future. “Single-domain antibodies are attractive probes for targeted radionuclide therapy and imaging due to their high binding specificity, sub-nanomolar affinity and low immunogenicity. The findings outlined in this publication demonstrate the potential of iodinated single domain antibodies to serve as imaging agent and therapy for cancer patients,” said Lahoutte.

This study was made available online in December 2020 ahead of final publication in print in August 2021.

The authors of “Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients,” include Matthias D’Huyvetter, Jos L.E. Eersels and Nick Devoogdt, Precirix NV/SA, Brussels, Belgium, and In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium; Jens De Vos, Precirix NV/SA, Brussels, Belgium; Vicky Caveliers and Marleen Keyaerts, Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium, and Nuclear Medicine Department, UZ Brussel, Brussels, Belgium; Ilse Vaneycken, Johannes Heemskerk, Hendrik Everaert and Pieterjan Gykiere, Nuclear Medicine Department, UZ Brussel, Brussels, Belgium; Francois P. Duhoux, Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Christel Fontaine, Department of Medical Oncology, UZ Brussel, Brussels, Belgium; Marian Vanhoeij, Department of Oncological Surgery, UZ Brussel, Brussels, Belgium; Albert D. Windhorst, Frank van der Aa and N. Harry Hendrikse, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Geert Raes, Precirix NV/SA, Brussels, Belgium, Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium, and Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium; and Tony Lahoutte, Precirix NV/SA, Brussels, Belgium, In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium, and Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.

Visit JNM’s new website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected]

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 11 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.

 



Journal

Journal of Nuclear Medicine

DOI

10.2967/jnumed.120.255679

Method of Research

Randomized controlled/clinical trial

Subject of Research

People

Article Title

Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients

Article Publication Date

1-Aug-2021

COI Statement

Marleen Keyaerts and Tony Lahoutte are senior clinical investigators and Matthias D’Huyvetter is postdoctoral researcher of the Research Foundation-Flanders. Francois Duhoux received a postdoctoral clinical mandate (2017-034) from the Foundation Against Cancer. This research was funded by Innoviris.Brussels (RBC/ 2014-R-75). Geert Raes, Nick Devoogdt, and Tony Lahoutte are consultants for Precirix NV/SA and, together with Matthias D’Huyvetter and Jens De Vos, hold ownership interest in Precirix NV/SA. Marleen Keyaerts, Geert Raes, Nick Devoogdt, and Tony Lahoutte hold ownership interest in Abscint NV/SA. Tony Lahoutte is a member of the scientific advisory board of Ion Beam Applications (IBA) and a member of the strategic committee of the Institute of RadioElements (IRE). Marleen Keyaerts has received travel and accommodation expenses from Bayer NV. Nick Devoogdt has received funding for preclinical research from Boehringer-Ingelheim, Complix, Confo Therapeutics, Roche, 121BIO, Agenus, and Telix Pharma. Marleen Keyaerts, Nick Devoogdt, Marleen D’Huyvetter, Jens De Vos, Tony Lahoutte, and Geert Raes have patents on sdAb imaging and therapy. Francois Duhoux holds advisory/consultancy roles for Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer, Pierre Fabre, Roche, and Teva (paid to the institution, outside the submitted work); has received speaker fees from Eli Lilly, Mundi Pharma, Novartis, Pfizer, and Roche (paid to the institution, outside the submitted work); and has received travel support from Amgen, Pfizer, Roche, and Teva. No other potential conflict of interest relevant to this article was reported.

Tags: breastcancerHER2positiveidentifiedPatientsradionuclidetherapy
Share26Tweet16Share5ShareSendShare
  • Multiple Sclerosis Prevalence in Black Americans

    Multiple sclerosis more prevalent in Black Americans than previously thought

    70 shares
    Share 28 Tweet 18
  • UTHSC researchers’ work on human pangenome aids understanding of common chromosomal abnormality

    70 shares
    Share 28 Tweet 18
  • Weather anomalies are keeping insects active longer

    66 shares
    Share 26 Tweet 17
  • American Indian and Alaska native men less likely to receive prostate cancer screening

    65 shares
    Share 26 Tweet 16
  • Whales not to be counted on as ‘climate savers’: study

    65 shares
    Share 26 Tweet 16
  • University of Sydney launches innovative research fellowship scheme to tackle global challenges

    65 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Null results research now published by major behavioral medicine journal

Why expensive wine appears to taste better

UTHSC researchers’ work on human pangenome aids understanding of common chromosomal abnormality

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 206 other subscribers

© 2023 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2023 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In